Initial management of Parkinson's disease

You are going to have to ask for the unproven strategies/ risks vs. benefits. This is the same lazy bullshit stroke doctors play so they don't have to actually work at their job. In stroke the excuse is;
'There is no clinical research for any neuroprotective treatment in the first week' 
You are going to have to solve Parkinsons on your own just like you would solve stroke rehabilitation on your own. Does your doctor know about ANY of these?

1.  Design of micro and nanoparticles to improve treatments for Alzheimer's and Parkinson's

2.  How coffee protects against Parkinson’s

3.  Possible treatment and Prevention for Parkinson’s

4.  Save the Neurons: Fighting the Effects of Parkinsons

5.  Alzheimer's, Parkinson's groups team up for research

6.  Statins protective against Parkinson's: More evidence

7.  Study Shows That Vibroacoustic Therapy is More Than Just Noise

8.  Engineers design a device to stabilize tremor in daily tasks for people with Parkinson’s

9.  6 Surprising Ways to Reduce Your Parkinson's Risk

10.  How Math Could Improve Life for Nearly 6 Million With Parkinson's

11.  Turning urine into brain cells could help fight Alzheimer’s, Parkinson’s

12.  Study: Biking Restores Brain Connectivity in Parkinson's 

Initial management of Parkinson's disease

Goetz CG¹, Pal G².

Author information

Abstract

Parkinson's disease is one of the most common neurodegenerative disorders seen in the United States and United Kingdom. The disease is characterised by two processes-cellular degeneration and the resulting biochemical deficiency of dopamine. Although these processes are inter-related, they are approached separately in the clinical setting. Currently, no proven neuroprotective or disease modifying treatment is available for Parkinson's disease. Several agents can be used to treat the motor symptoms associated with dopamine deficiency, and it is important to choose wisely when starting treatment. Drugs can have mild, moderate, or high potency, and the patient's goals, comorbidities, and the short and long term implications of choosing a specific agent should be taken into account when selecting the appropriate agent. Non-motor symptoms, such as depression, fatigue, and disorders of sleep and wakefulness, also need to be evaluated and treated. Research is under way to deliver dopaminergic therapy more effectively, but studies aimed at slowing or stopping disease progression have not shown promise.